Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus mFOLFOX6 versus placebo plus mFOLFOX6 in first-line CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma
2024-511365-11-00Phase 3Authorised
- Sponsor
- Astellas Pharma
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Zolbetuximab plus mFOLFOX6 with Placebo plus mFOLFOX6 (2 arms). Primary endpoint: Progression-free survival. Planned start Nov 2018; status: authorised.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-511365-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511365-11-00.